CLINICAL STUDY RESULTS

In 2 large phase 3 trials, SARCLISA was proven to help more people live progression free

Nearly 3 out of 4 people treated with SARCLISA + Kd
                    lived progression free Nearly 3 out of 4 people treated with SARCLISA + Kd
                    lived progression free

people treated with SARCLISA + Kd lived progression free

At an average follow-up of 20.7 months, 74% (133 of 179 people) lived progression free with SARCLISA + Kd vs 59% (73 of 123 people) treated with Kd alone.


Around half of people treated with SARCLISA + Pd
                    lived progression free Around half of people treated with SARCLISA + Pd
                    lived progression free

of people treated with SARCLISA + Pd lived progression free

At an average follow-up of 11.6 months, 53% (81 of 154 people) lived progression free with SARCLISA + Pd vs 42% (64 of 153 people) treated with Pd alone.

At this time, there are not enough data available from the trials to assess whether people receiving SARCLISA + Kd or SARCLISA + Pd lived longer.

Trial 1: In a clinical trial of 302 people with previously treated multiple myeloma who had received 1 to 3 prior treatments, 179 people received SARCLISA + Kd and 123 people received Kd alone.

Trial 2: In a clinical trial of 307 people with previously treated multiple myeloma who had received at least 2 prior treatments, including Revlimid® (lenalidomide) and a proteasome inhibitor,* 154 people received SARCLISA + Pd and 153 people received Pd alone.

Both trials compared how long people lived without their disease getting worse and how people responded to treatment.

*Examples of proteasome inhibitors include Kyprolis, Ninlaro® (ixazomib), and Velcade® (bortezomib).

The majority of people responded to treatment with SARCLISA

Alt tag: 87% of people treated with SARCLISA + Kd responded
                    to treatment Alt tag: 87% of people treated with SARCLISA + Kd responded
                    to treatment

responded to SARCLISA + Kd


60% of people treated with SARCLISA +Pd
                    responded to treatment 60% of people treated with SARCLISA +Pd
                    responded to treatment

responded to SARCLISA + Pd

vs 35% responded to treatment with Pd alone.